

Quality of life in patients with advanced gastric cancer: a randomized trial comparing docetaxel, cisplatin and 5-fluorouracil against epirubicin, cisplatin and 5-fluorouracil

Submission date 03/07/2006	Recruitment status No longer recruiting	<input type="checkbox"/> Prospectively registered <input type="checkbox"/> Protocol
Registration date 28/07/2006	Overall study status Completed	<input type="checkbox"/> Statistical analysis plan <input checked="" type="checkbox"/> Results
Last Edited 25/09/2009	Condition category Cancer	<input type="checkbox"/> Individual participant data

Plain English summary of protocol

Not provided at time of registration

Contact information

Type(s)

Scientific

Contact name

Dr Sanambar Sadighi

Contact details

Cancer Institute

Emam Hospital

Tehran

Iran

-

ssadighi@doctor.com

Additional identifiers

EudraCT/CTIS number

IRAS number

ClinicalTrials.gov number

Secondary identifying numbers

N/A

Study information

Scientific Title

Study objectives

Quality of life does not differ in advanced gastric cancer patients after receiving either docetaxel, cisplatin and 5-fluorouracil (5-FU) (TCF regiment) versus epirubicin, cisplatin and 5-FU (ECF-regimen).

Ethics approval required

Old ethics approval format

Ethics approval(s)

Ethics committee of the Tehran University of Medical Sciences November 2001

Study design

Randomised controlled trial

Primary study design

Interventional

Secondary study design

Randomised controlled trial

Study setting(s)

Not specified

Study type(s)

Treatment

Participant information sheet

Health condition(s) or problem(s) studied

Gastric cancer

Interventions

Three to six cycles of either ECF (epirubicin 60 mg/m², cisplatin 60 mg/m² and 5-FU 750 mg/m²/day as a five-day continuous infusion) or TCF regimen (docetaxel 60 mg/m², cisplatin 60 mg/m² and 5FU in the same dose and schedule of ECF) every three weeks.

Intervention Type

Other

Phase

Not Specified

Primary outcome measure

Response rate

Secondary outcome measures

Quality of life and survival

Overall study start date

01/01/2002

Completion date

01/01/2005

Eligibility

Key inclusion criteria

Patients with histologically confirmed advanced gastric cancer

Participant type(s)

Patient

Age group

Adult

Sex

Both

Target number of participants

86

Key exclusion criteria

Patients with local or local- regional gastric cancer

Date of first enrolment

01/01/2002

Date of final enrolment

01/01/2005

Locations

Countries of recruitment

Iran

Study participating centre

Cancer Institute

Tehran

Iran

-

Sponsor information

Organisation

Tehran University of Medical Sciences (Iran)

Sponsor details

Enghelab Avenue

Tehran

Iran

-

info@sina.tums.ac.ir

Sponsor type

University/education

ROR

<https://ror.org/01c4pz451>

Funder(s)

Funder type

University/education

Funder Name

Tehran University of Medical Sciences (Iran)

Results and Publications

Publication and dissemination plan

Not provided at time of registration

Intention to publish date

Individual participant data (IPD) sharing plan

IPD sharing plan summary

Not provided at time of registration

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Results article	results	05/12/2006		Yes	No

